| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 64 | GB 11 | 99.75 |
| Lipoproteins and Cardiovascular Health | Lifetime | 30 | GB 3 | 99.81 |
| Pharmaceutical Economics and Policy | Lifetime | 12 | GB 1 | 99.40 |
| Cancer, Lipids, and Metabolism | Lifetime | 49 | GB 7 | 99.74 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 53 | GB 7 | 99.71 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 161 | GB 13 | 98.68 |
| Diabetes Treatment and Management | Lifetime | 276 | GB 29 | 98.89 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 226 | GB 16 | 98.85 |
| Lipid metabolism and disorders | Lifetime | 167 | GB 15 | 97.95 |
| Acute Myocardial Infarction Research | Lifetime | 710 | GB 35 | 97.93 |
| Nuclear Receptors and Signaling | Lifetime | 688 | GB 42 | 91.72 |
| Aortic Thrombus and Embolism | Lifetime | 270 | GB 12 | 82.95 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 2 | GB 1 | 99.89 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 4 | GB 1 | 99.90 |
| Pharmaceutical Economics and Policy | 2021-2025 | 2 | GB 1 | 99.42 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 6 | GB 1 | 99.81 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 12 | GB 1 | 99.68 |
| Lipid metabolism and disorders | 2021-2025 | 4 | GB 1 | 99.00 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 19 | GB 3 | 99.23 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 29 | GB 3 | 97.61 |
| Nuclear Receptors and Signaling | 2021-2025 | 53 | GB 2 | 88.63 |
| Diabetes Treatment and Management | 2021-2025 | 768 | GB 68 | 92.26 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 668 | GB 50 | 91.61 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 497 | GB 32 | 82.30 |
| Ginkgo biloba and Cashew Applications | 2021-2025 | 539 | GB 19 | 48.99 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 900 | GB 115 | 45.20 |
